Evaluation of the effectiveness and safety of a daily dose of 5mg of tadalafil, over an 8-week period, for improving quality of life among Korean men with andropause symptoms, including erectile dysfunction

A pilot study

Joong Gyo Lee, MDa, Byung Duk Kim, MDa, Chang Hee Han, MD, PhDb, Kang Kon Lee, MD, Phdc, Keun Sang Yum, MD, PhDd

Abstract

Background: The primary aim of this study was to evaluate the effects of a once-a-day 5mg dose of tadalafil, prescribed for 8 weeks, on the quality of life (QoL) of South Korean men with andropause symptoms, including erectile dysfunction (ED), using a single group, open-labeled, before-and-after preliminary trial. The secondary objective was to evaluate the effectiveness and safety of tadalafil for ED.

Methods: Forty South Korean men (>35 years of age) with andropause symptoms including ED were enrolled into our trial. Andropause syndrome was defined using the androgen deficiency in aging males (ADAM) questionnaire and other screening tests, including testosterone levels. The following outcome measures were obtained at baseline and at 4 and 8 weeks of tadalafil treatment: physical examination, adverse effects, Short Form 12 Health Survey (SF-12) score, International Index of Erectile Function (IIEF-5) score, bioelectrical impedance analysis (BIA), and free radical testing.

Results: Treatment increased the SF-12 Mental component score, used as a proxy measure of quality of life, from baseline to at 4 and 8 weeks (P < .05). In addition, the mean IIEF-5 score, which assesses sexual function, increased from baseline at 4 and 8 weeks (P < .05), with this increase being significant at both time points. No adverse effects were noted.

Conclusion: Tadalafil (5 mg dose, once daily) is a safe and effective treatment to improve ED, and overall QoL, among Korean men with andropause symptoms, including ED.

Abbreviations: ADAM = androgen deficiency in aging males, BIA = bioelectrical impedance analysis, BMI = body mass index, BPH = benign prostatic hypertrophy, cGMP = cyclic guanosine monophosphate, CV = coefficient of variation, ED = erectile dysfunction, GH = general health, IIEF-5 = International Index of Erectile Function-5, IPSS = International Prostate Symptom score, MCS = mental component score, MH = mental health, NO = nitric oxide, QoD = once daily, PCS = physical component score, POE-5i = phosphodiesterase type 5 inhibitors, QoL = quality of life, RE = role—emotional, SD = standard deviation, SF-12 = Short Form 12 Health Survey, SHBG = sexual hormone-binding globulin, TRT = testosterone-replacement therapy.

Keywords: andropause, erectile dysfunction, quality of life, tadalafil

1. Introduction

With aging of the general population, there has been an increasing interest in the care of men with andropause symptoms and their quality of life (QoL). A study of late-onset hypogonadism, conducted in Korea, reported that 64.6% of men between the ages of 40 and 70 years may experience andropause syndrome, with erectile dysfunction (ED) being the most frequent symptom, reported in 71% of cases.[1]

Andropause syndrome is an age-related clinical and biochemical syndrome that is characterized by symptoms of ED and testosterone deficiency, with a resultant significant decrease in QoL; it also adversely affects the functions of multiple tissues and organs, including bone, fat tissue, muscle, hematopoiesis, brain, and skin. [2] The typical clinical symptoms of andropause syndrome can be summarized into 3 categories: changes in physical characteristics (abdominal obesity, decreased muscle mass and strength, decreased bone mineral density, decrease in body hair, and skin alterations), changes in mood (depression, decreased concentration and cognitive function, and increased fatigue), and decreased sexual function (diminished libido and erectile quality).[3]
Penile erection is mainly mediated by the neurotransmitter nitric oxide (NO), via cyclic guanosine monophosphate (cGMP). Phosphodiesterase type 5 inhibitors (PDE-5I) inhibit the hydrolysis of cGMP into GMP, causing an increase in NO to relax smooth muscle and increase blood flow, thereby facilitating the erectile response.\[^1\]

Tadalafil, which is currently used for the treatment of ED, inhibits the PDE-5 enzyme to maintain an erection. A previous study evaluated the effects of different doses of tadalafil on erectile function, compared to those of a placebo.\[^3\] This study found that a pro re nata tadalafil dose of 2.5 or 5 mg, taken once daily (OaD) for 12 weeks, improved andropause symptoms including erectile function.

Giuliano et al\[^6\] conducted a study based on the assumption that treatment using sildenafil (PDE-5I), another inhibitor of PDE-5, would improve ED symptoms and, consequently, improve the QoL of men with ED. These authors reported an improvement in QoL parameters related to sexual function, as well as improvement in the medical outcomes study and Short Form 12 Health Survey (SF-12), indicating that andropause symptoms, including ED, influence overall QoL, rather than merely causing discomfort. Novák et al\[^7\] indicated that andropause syndrome affects all areas of QoL, including vitality, physical, emotional, mental, social, and sexual function. In particular, ED has been associated with a loss of meaning and value of life, as well as leading to psychological frustration, feelings of helplessness and shame, family disagreement, social conflict, and lower self-confidence, as well as having an adverse effect on couple intimacy and sex life harmony.\[^7\]–\[^9\]

Considering that the ultimate goal of treatment for men with andropause symptoms, including ED, is not only to improve ED symptoms but also to improve overall QoL, our primary aim in this study was to evaluate the effects of a 5 mg OaD dose of tadalafil, prescribed for 8 weeks, on QoL of Korean men with andropausal symptoms, including ED, using a single group, open-labeled, before-and-after preliminary trial. The secondary objective was to evaluate the effectiveness and safety of the 5 mg OaD dose of tadalafil on ED in order to confirm previously reported findings on the safety of this drug for the treatment of ED.

### 2. Materials and methods

#### 2.1. Study design and participants

Men > 35 years of age, who sought consultation and treatment for ED at the University Hospital in Northern Gyeonggi, South Korea, between March and May 2016, were recruited for participation. After providing informed consent, participants underwent screening with those meeting our eligibility criteria (Table 1) being enrolled. The relevant general characteristics of our study group, such as age, marital status, education, and smoking and drinking habits, are summarized in Table 2.

The study was approved by the Institutional Review Board of the Catholic Medical Center’s Research Ethical Committee (UC16MISV0046), and the trial was registered (ClinicalTrial.gov Identifier: NCT02943356).

#### 2.2. Protocol and evaluation

Participants were given an enrollment number and received a 5 mg OaD dose of tadalafil for 8 weeks. The following outcome measures were collected for analysis: SF-12 score, IIEF-5 score, serum levels of testosterone, bioelectrical impedance analysis (BIA) of body composition, and free radical testing. All outcome measures were obtained at baseline, at the mid-point of the treatment period (4 weeks) and at the end of the treatment period (8 weeks). In addition, physical examination, including vital signs, and adverse effect monitoring were performed to evaluate drug safety, with measures also obtained at baseline and at 4 and 8 weeks (Fig. 1). Evaluation at the mid-point of the treatment period (4 weeks) was included to monitor for adverse effects of tadalafil, as well as to measure the time-dependent improvement

| Table 1 |
| --- |
| **Inclusion and exclusion criteria.** |
| **Inclusion criteria** |
| 1) Answering “yes” to items 1 or 7 among the 10 items of the ADAM questionnaire or answering “yes” to more than 3 items on the questionnaire |
| 2) Complaints of andropause symptoms, such as fatigue, loss of sexual function, depression, hot flashes, and memory impairment |
| 3) Complaints of erectile dysfunction for > 6 mo and a score of ≥ 21 points on the IIEF-5 |
| 4) Patient’s willingness to participate in the present study and sign the written consent to receive ED treatment with tadalafil 5 mg OaD for 8 weeks |
| **Exclusion criteria** |
| 1) Prescription of PDE-5I for ED within the last 1 mo |
| 2) History of testosterone replacement therapy |
| 3) Currently taking any organic nitrate drug regularly and/or intermittently |
| 4) History of cardiovascular or cerebrovascular disease |
| 5) Uncontrolled arrhythmia, hypertension (<90/50 mm Hg), or uncontrolled hypertension (>170/100 mm Hg) |
| 6) Degenerative retinopathy, including pigmentary retinitis |
| 7) One eye blindness caused by ischemic optic neuropathy, regardless of previous use of PDE-5I |
| 8) Taking any drug that inhibits or activates hepatic cytochrome P4503A4 (e.g., cimetidine, ketoconazole, erythromycin class drugs) |
| 9) Concomitant use of α-blockers and antihypertensive drugs |
| 10) Severe hepatic or renal impairment |
| 11) Major psychiatric or psychological disorders (including major depression) |
| 12) Hypersensitivity to the study drug |
| 13) History of urogenital surgery including prostate surgery or other invasive procedures to treat the prostate gland |
| 14) Congenital penile deformities |
| 15) Genetic conditions, such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption |
| 16) Being deemed ineligible for the present study by the researchers |

ADAM = androgen deficiency in aging males, ED = erectile dysfunction, IIEF-5 = International Index of Erectile Function, PDE-5I = phosphodiesterase type 5 inhibitors.

* Three conditions or more must be satisfied: 1), 3), 4); 2), 3), 4); or 1), 2), 3), 4).
effect on QoL. The severity of adverse effects was classified based on the following 3 grades: grade 1, mild; grade 2, moderate; and grade 3, severe. The degree of causality between tadalafil and adverse effects was evaluated on a 5-point scale: 1, definitely related; 2, probably related; 3, possibly related; 4, unlikely related; and 5, not related.

### Table 2
General characteristics of the study group (n = 40).

| Variable                   | Classification       | Number of patients (%) |
|----------------------------|----------------------|------------------------|
| Age, y                     | 35–39                | 2 (5%)                 |
|                           | 40–49                | 10 (25%)               |
|                           | 50–59                | 20 (50%)               |
|                           | 60–69                | 8 (20%)                |
| Average                   |                      | 53.34±7.55             |
| Marital status            | Married              | 39 (97.5%)             |
|                           | Unmarried            | 1 (2.5%)               |
| Educational level         | Graduate school      | 3 (7.5%)               |
|                           | University           | 28 (70%)               |
|                           | High school          | 9 (22.5%)              |
|                           | Middle school        | 0 (0%)                 |
|                           | Elementary school    | 0 (0%)                 |
| Drinking                  | Yes                  | 22 (55%)               |
|                           | No                   | 18 (45%)               |
| Smoking                   | Yes                  | 7 (17.5%)              |
|                           | No                   | 33 (82.5%)             |
| Height, cm                | Baseline             | 172.90±5.70            |
| Weight, kg                | Baseline             | 76.10±11.00            |
| BMI, kg/m²                | Baseline             | 25.38±2.38             |

Data are presented as mean±standard deviation or as n (%). BMI = body mass index.

### 2.3. Screening measures

#### 2.3.1. Androgen deficiency in aging males (ADAM) questionnaire.
Andropause symptoms were measured using the Korean version of the ADAM questionnaire, originally developed by Morley et al[10] and translated into Korean by Kim et al.[11] The questionnaire consists of 10 items evaluating libido, energy, strength and endurance, height, enjoyment of life, feelings of sadness and moodiness, erections, and the ability to play sports, to sleep, and to work. The questionnaire uses a dichotomous “yes” or “no” answer scale. Positive responses to questions regarding libido or erection, as well as a positive answer on ≥3 of the remaining items were used as criteria for andropause syndrome.[1,12]

### 2.4. Outcome measures

#### 2.4.1. Observational and clinical tests.
Demographic and anthropometric measurements were obtained at baseline (Table 2), with social factors obtained through history-taking during the screening visit. The medical records of individuals enrolled onto the study were reviewed to obtain the medical history within the last 6 months, as well as medication history. Results of the physical examination, including vital signs, and laboratory tests performed, are reported in Table 3.

#### 2.4.2. SF-12 questionnaire.
Health-related QoL was measured using the Korean version of SF-12, which is adapted from the original developed by Ware et al,[13] and used in this study with permission from the copyright owner, QualityMetric Incorporated. The instrument consists of 12 items measuring 2 component scores, the Physical Component Score (PCS) and the Mental Component Score (MCS), with the response scales for...
each item varying between 2, 4, and 6 points. The PCS includes the evaluation of physical functioning, role—physical, bodily
pain (BP), and general health (GH), while the MCS evaluates vitality, social functioning, role—emotional (RE), and mental
health (MH). The overall health score is quantified as
the weighted average of all 8 domains. The QoL score on the SF-12
was calculated using the method provided by QualityMetric
Incorporated, with a higher score indicative of a higher QoL. The
reliability of the SF-12 has previously been established
(Cronbach’s $\alpha$, 0.81–0.84).[14]

2.4.3. The IIEF-5 questionnaire. The IIEF-5 questionnaire is
an abridged version of IIEF designed to the severity of ED. The
questionnaire consists of 5 items evaluating the satisfaction with
erectile function and sexual intercourse. Each item is scored on a
5-point scale, from “0” to “5,” and the scores for each item are
summed to yield a total score.[15]

2.4.4. BIA and free radical test. BIA (Biodynamics BIA 450,
Biodynamics Corporation, Seattle, Washington, DC) measures
body composition by passing a low-level electrical current
through the body to determine the bioelectrical impedance to.
The BIA method has been widely used to assess body composition
across a variety of diseases and health statuses, including obesity,
diabetes mellitus, heart failure, and hemodialysis.[16] From this
perspective, BIA could be useful to evaluate possible associations
between body composition and QoL. All BIA analyses were
performed with participants in the supine position, on a
nonconductive surface, with electrodes placed on the right hand
and foot. Six components of the BIA were measured, and all
assessments were performed by the same evaluator.

Free radicals are by-products of the metabolic processes of the
body and are “harmful oxygen” molecules associated with cell
apoptosis and the development of several diseases, including
different types of cancers, chronic diseases, and aging. The FORT
free radical test measures the level of free radicals in the body, with
levels referenced to the standard level 600,$^{[17,19]}$ classified as follows:
>600, very severe oxidative stress; 401 to 600, high oxidative
stress; 341 to 400, moderate oxidative stress; 311 to 340, low
oxidative stress; 231 to 300, cautionary levels of oxidative stress;
160 to 230, normal level; and <160, requiring consultation. The
free radical test was measured using a spectrophotometer, at a
wavelength of 505 nm (Form CR 2000, Callegari, Parma, Italy),
with intra- and interassays coefficients of variation (CV) of <5%,
and a sensitivity of 4.0528. When measuring a known concentration
of control serum (control substance), the specificity is within
±10% of the known concentration.

2.4.5. Total testosterone level. Testosterone is a steroid male
hormone (androgen) produced by male testicular endocrine tissue
(Leydig cells). Testosterone determines secondary sex character-
istics, sexual desire, and erection, as well as increases metabolic
processes in muscles, bones, bone marrow, the immune system,
and the brain.[18]

Total testosterone level was measured from venous blood
samples in the fasting state, in the morning (7–11 AM), with
measured levels normalized for age and classified into normal
(≥3.5 ng/mL) and low (<3.5 ng/mL) levels. Analyses were
performed using GAMMACOUNTER (Cobra5010, Canberra
Packard, Pangebourne, UK), with a CV of <10% (range, 3.3–
6.2%) for intra- and interassay precision.

2.5. Sample size and statistical analysis

2.5.1. Sample size. The primary outcome of our study was the
change in the SF-12 QoL score, with the changes in BIA, free
radical level, and IIEF-5 score being evaluated as secondary
outcomes. Quantitative variables were reported as the mean ±
standard deviation (SD) or median, as appropriate, with
qualitative variables reported as count and proportion (n, %).
Using the methods of Tong et al. [19] the sample size was
calculated assuming a change of 8.78 points on the SF-12 QoL
score, with a SD of 17 points. Sample size calculation was
performed using PASS 12 (NCSS, LLC., Kaysville, UT), with 32
participants required to detect a change in QoL at a level of
significance of 0.05 and power of 80%. Considering a dropout
rate of 20%, 40 participants were enrolled into the study.

2.5.2. Statistical analysis. As all 40 participants completed the
study protocol, the full analysis set and the per-protocol analysis
set included the 40 participants in the assessment of QoL, changes
in IIEF-5 score, SF-12 score, BIA, and free radical testing before
and after tadalafl administration. For further safety evaluation,
adverse effects, vital signs (blood pressure, pulse, and body
temperature), and physical examination were used as input
variables. Statistical analysis was performed using SPSS (version
17, IBM Corp, Armonk, NY). The paired $t$ test was used to
evaluate the change in score from baseline, with the Wilcoxon
signed rank test being used when normality was not verified, as
determined using the Shapiro–Wilk test. A $P$ value <.05 was
considered statistically significant.

3. Results

3.1. Study participants

Of the 102 men who sought treatment in our clinic during the
study period (8 weeks), 40 met our inclusion and exclusion
criteria and were enrolled into the trial. The other 82 were
excluded due to not meeting the inclusion criteria (42), declining
to participate (32), and 8 due to other reasons. All 40 participants
enrolled completed all components of the study protocol.
3.2. General characteristics of the study participants

Relevant characteristics of our study group are reported in Table 2, and summarized as follows: age, 53.34 ± 7.55 years (range, 40–59 years); height 172.90 ± 5.70 cm; weight, 76.10 ± 11.00 kg; body mass index (BMI), 25.38 ± 2.38 kg/m²; all participants, with the exception of one, were married; 77.5% had a college education or above; 22 participants (55.00%) consumed alcohol regularly; and 7 (17.50%) were smokers.

3.3. Testosterone level and ADAM questionnaire

With regards to testosterone level, 30 participants (75.0%) had normal levels and 10 (25%) had low levels (Table 4). On the ADAM questionnaire, 30 participants (75.0%) reported a decrease in libido, with 5 (12.5%) reporting a decrease in the rigidity of penile erection. In addition, 24 participants (60.0%) reported a lack of energy, 30 (75.0%) reported a decrease in strength and/or endurance, 11 (27.5%) reported decreased height, 11 (27.5%) reported a decreased enjoyment of life, 10 (25.0%) reported being sad and/or moody, 10 (25.0%) reported a recent deterioration in their ability to play sports, 15 (37.5%) required sleep after dinner, and 17 (42.40%) reported a recent deterioration in their work performance (Table 5).

3.4. Vital signs and physical examination

There was an overall decrease in systolic blood pressure, from baseline, of 1.38 ± 12.70 mm Hg at 4 weeks and 2.28 ± 13.35 mm Hg at 8 weeks of treatment, with a decrease in diastolic blood pressure of 1.60 ± 7.85 mm Hg at 4 weeks and 1.15 ± 8.82 mm Hg at 8 weeks. There was an increase in pulse rate, from baseline, of 0.55 ± 3.77 beats/min at 4 weeks and 1.08 ± 4.72 beats/min at 8 weeks, whereas the body temperature decreased by 0.03 ± 0.30°C at 4 weeks and 0.05 ± 0.38°C at 8 weeks. The change in vital signs from week 4 to week 8 was nonsignificant (Table 6). The physical examination of all participants was within normal limits at all measurement time points.

3.5. Change in the SF-12 scores

There was an overall nonsignificant increase in PCS, from baseline, of 0.47 ± 5.63 at 4 weeks and 0.73 ± 7.07 at 8 weeks. By item, there was a significant increase, from baseline, in the GH score of 3.43 ± 7.41 at 4 weeks and 3.33 ± 7.50 at 8 weeks. Other increases in specific item scores, reported in Table 7, included: MCS, 4.85 ± 8.15 at 4 weeks and 4.39 ± 8.48 at 8 weeks (both significant); vitality, 3.44 ± 10.58 at 4 weeks (nonsignificant) and 3.93 ± 9.91 at 8 weeks (significant); RE, 3.86 ± 9.14 at 4 weeks and 3.60 ± 8.94 at 8 weeks (both significant); and MH, 5.16 ± 9.07 at 4 weeks and 3.73 ± 7.64 at 8 weeks (significant).

Table 4

| Age | Normal (3.5–9ng/mL) | Low (< 3.5ng/mL) | Number of patients (%) |
|-----|---------------------|------------------|------------------------|
| 30–39 | 2 (5%) | 0 (0%) | 2 (5%) |
| 40–49 | 5 (12.5%) | 5 (12.5%) | 10 (25%) |
| 50–59 | 15 (37.5%) | 5 (12.5%) | 20 (50%) |
| 60–69 | 8 (20%) | (0%) | 8 (20%) |
| Total (%) | 30 (75%) | 10 (25%) | 40 (100%) |

Table 5

| Questions | Response | Number of patients (%) |
|-----------|----------|------------------------|
| 1. Do you have a decrease in libido (sex drive)? | Yes | 30 (75.00%) |
| | No | 10 (25.00%) |
| 2. Do you have a lack of energy? | Yes | 24 (60.00%) |
| | No | 15 (37.50%) |
| 3. Do you have a decrease in strength and/or endurance? | Yes | 30 (75.00%) |
| | No | 9 (22.50%) |
| 4. Have you lost height? | Yes | 11 (27.50%) |
| | No | 29 (72.50%) |
| 5. Have you noticed a decreased "enjoyment of life"? | Yes | 11 (27.50%) |
| | No | 29 (72.50%) |
| 6. Are you sad and/or grumpy? | Yes | 10 (25.00%) |
| | No | 29 (72.50%) |
| 7. Are our erections less strong? | Yes | 5 (12.50%) |
| | No | 34 (85.00%) |
| 8. Have you noted a recent deterioration in your ability to play sports? | Yes | 10 (25.00%) |
| | No | 29 (72.50%) |
| 9. Are you falling asleep after dinner? | Yes | 15 (37.50%) |
| | No | 24 (60.00%) |
| 10. Has there been a recent deterioration in your work performance? | Yes | 17 (42.50%) |
| | No | 23 (57.50%) |

A positive questionnaire result is defined as a “Yes” answer to question 1 or 7 or any 3 other questions.

* Numbers vary due to missing data.

Table 6

| Vital sign and physical measurement scores at 4 and 8 weeks. |
|------------------------------------------------------------|
| Variables after 4 wk compared to baseline                  |
| Variable | Baseline | 4 wk | P     |
|-----------|----------|------|-------|
| SBP, mm Hg | 127.55 ± 11.09 (128) | 127.98 ± 8.91 (125.50) | .44 |
| DBP, mm Hg | 74.48 ± 7.36 (75.00) | 72.88 ± 7.15 (72.50) | .20 |
| Pulse, beats/min | 73.50 ± 11.10 (73.00) | 74.05 ± 9.81 (72.00) | .25 |
| Body temperature, °C | 36.80 ± 30 (36.80) | 36.74 ± 23 (36.80) | .57 |

Variables after 8 wk compared to baseline

| Variable | Baseline | 8 wk | P     |
|-----------|----------|------|-------|
| SBP, mm Hg | 127.55 ± 11.09 (128) | 125.28 ± 10.86 (126.00) | .33 |
| DBP, mm Hg | 74.48 ± 7.36 (75.00) | 73.93 ± 6.81 (73.00) | .41 |
| Pulse, beats/min | 73.50 ± 11.10 (73.00) | 74.58 ± 11.91 (72.50) | .16 |
| Body temperature, °C | 36.80 ± 30 (36.80) | 36.71 ± 24 (36.70) | .33 |

Data are presented as mean ± standard deviation (median).

SBP = systolic blood pressure, DBP = diastolic blood pressure.
3.6. Change in BIA and free radical test

There was no change in BIA variables at either 4 or 8 weeks. The mean free oxygen radical level at baseline was 283.48 ± 25.22 (CARR U), classified as a cautionary level, with a nonsignificant increase, from baseline, of 9.18 ± 3.69 points at 8 weeks. The use of combined medications was not a contraindication in our protocol.

3.7. Change in IIEF-5 scores

The mean IIEF-5 score, which assesses sexual function, increased significantly from baseline, by 4.10 ± 5.52 points at 4 weeks and 3.33 ± 4.77 points at 8 weeks (Table 9).

3.8. Safety outcomes

With regard to adverse effects, the following were observed: 1 case (2.5%) of stomatitis at baseline; 5 cases (12.50%) of dyspnea, fatigue, hand tingling, swelling around the eye, and muscle tension at 4 weeks; and 2 cases (5.0%) of tingling of the feet and nausea at 8 weeks. All adverse effects at 4 and 8 weeks were considered to be mild. On evaluation of the causal relationship between the drug and the adverse effects, all cases were deemed “unlikely” or “not” related to the drug. Twenty-four participants (60.0%) reported taking other medications before the study, with 26 participants (65.0%) taking a combination of medications at 4 weeks and 25 (62.5%) at 8 weeks. The use of combined medications was not a contraindication in our protocol.

4. Discussion

We conducted this pilot study to evaluate the possible clinical utility of tadalafil (5 mg, OaD) to improve the QoL of Korean men over 35 years old with andropause symptoms, including ED. The 5mg daily dose of tadalafil produced a significant improvement in the MCS component of QoL at 4 and 8 weeks. Specifically, we identified an increase in MH and RE (5.16 ± 3.86 and 3.86 ± 9.14, respectively) at 4 weeks, with a further increase

| Table 7: Short Form-12 questionnaire scores after 4 and 8 weeks. Variables after 4 wk compared to baseline | 4 wk | P  |
|---------------------------------------------------------------|------|----|
| PCS | 48.43 ± 8.14 (50.17) | 48.62 ± 6.55 (49.97) | .63 |
| Physical functioning | 48.18 ± 8.88 (49.19) | 48.99 ± 8.26 (49.19) | .20 |
| Role—physical | 49.23 ± 7.26 (49.00) | 50.27 ± 8.08 (53.23) | .07 |
| Bodily pain | 47.81 ± 9.54 (48.71) | 49.39 ± 8.76 (48.71) | .12 |
| General health | 41.14 ± 8.59 (47.75) | 44.57 ± 8.45 (47.75) | .0082 |
| MCS | 45.33 ± 9.21 (45.23) | 50.45 ± 9.04 (51.85) | .0013 |
| Vitality | 47.84 ± 8.68 (49.07) | 51.28 ± 9.31 (49.07) | .057 |
| Social functioning | 47.79 ± 8.66 (48.01) | 50.90 ± 8.40 (56.90) | .14 |
| Role—emotional | 43.62 ± 9.30 (45.89) | 47.71 ± 10.09 (51.08) | .012 |
| Mental health | 45.28 ± 9.56 (47.00) | 50.44 ± 9.44 (49.87) | .0015 |

| Variables after 8 wk compared to baseline | 8 wk | P  |
|------------------------------------------|------|----|
| PCS | 48.43 ± 8.14 (50.17) | 49.07 ± 7.43 (50.17) | .54 |
| Physical functioning | 48.18 ± 8.88 (49.19) | 48.60 ± 9.82 (53.13) | .61 |
| Role—physical | 49.23 ± 7.26 (49.00) | 49.95 ± 8.21 (51.12) | .49 |
| Bodily pain | 47.81 ± 9.54 (48.71) | 50.29 ± 8.88 (48.71) | .039 |
| General health | 41.14 ± 8.59 (47.75) | 44.47 ± 9.51 (47.75) | .019 |
| MCS | 45.33 ± 9.21 (45.23) | 49.45 ± 9.28 (51.52) | .016 |
| Vitality | 47.84 ± 8.68 (49.07) | 51.77 ± 9.18 (53.99) | .042 |
| Social functioning | 47.79 ± 8.66 (48.01) | 50.23 ± 7.99 (48.01) | .094 |
| Role—emotional | 43.62 ± 9.30 (45.89) | 47.75 ± 10.34 (48.49) | .035 |
| Mental health | 45.28 ± 9.56 (47.00) | 49.01 ± 10.19 (52.74) | .021 |

MCS = mental component score, PCS = physical component score.
* P < .05 statistically significant, compared to baseline; data are presented as mean ± standard deviation (median).

| Table 9: Bioelectrical impedance analysis and free radical test scores at 8 weeks. Variables 8 wk compared to baseline | 8 wk | P  |
|---------------------------------------------------------------|------|----|
| Phase angle, ° | 8.52 ± 2.69 | 7.97 ± 1.87 | .45 |
| Body capacitance, pf | 1065.35 ± 265.17 | 990.65 ± 225.01 | .143 |
| Lean body mass, kg | 81.74 ± 8.19 | 80.83 ± 8.60 | .16 |
| Fat mass, kg | 18.27 ± 9.18 | 19.18 ± 5.79 | .16 |
| Body mass index, kg/m² | 25.37 ± 2.83 | 25.22 ± 2.82 | .25 |
| Basal metabolic rate, kcal | 1928.10 ± 261.69 | 1901.75 ± 264.29 | .11 |
| Free radical, CARR U | 283.48 ± 41.53 | 292.65 ± 46.39 | .22 |

Data are presented as mean ± standard deviation.

| Table 9: International Index of Erectile Function-5 score at the 3 measurement time points. Variables 4 and 8 wk | 4 wk | 8 wk | P  |
|---------------------------------------------------------------|------|------|----|
| IIEF-5 | 12.20 ± 6.09 | 16.30 ± 5.01 | 15.53 ± 5.95 | <.001 |

IIEF-5 = International Index of Erectile Function-5. * P < .05 statistically significant, compared to baseline; data are presented as mean ± standard deviation (median).
in MH, RE, and vitality (3.73 ± 7.64, 3.60 ± 8.94, and 3.93 ± 9.91, respectively) at 8 weeks. On the other hand, although the mean change in PCS subitems increased from baseline at 4 and 8 weeks, only the change in GH was significant. Based on our results, we propose that tadalafl (at a dose of 5 mg, OaD) produced a significant improvement in the overall QoL in our study group. This improvement in QoL appears to be related to an increase in self-confidence associated with improved sexual function and sex life, and improved partner relationship, findings which are consistent with those of a previous study in which sildenafil (PDE-5I) was used.[7] The absence of an improvement in PCS likely reflects our exclusion of physical disease in our selection criteria. A previous study evaluating the clinical utility of tadalafl on QoL in patients with benign prostatic hyper trophy (BPH) reported a meaningful increase in the International Prostate Symptom Score (IPSS) within 1 week in 65% of patients, with a meaningful increase achieved in 80% of patients by 4 weeks. Therefore, our 8-week period of treatment was sufficient to evaluate meaningful effects.[20] In that study, however, it was not possible to ascertain that increases in the IPSS specifically reflected increases in QoL, as most of the IPSS indices were related to urinary symptoms, with only one index related to QoL. Despite this limitation, the study is significant in that it demonstrated the association between the use of tadalafl and QoL improvement. Another previous study also reported an improvement in erectile function among men with ED using tadalafl, with this increase improving the relationship between men and their wives and, therefore, their overall QoL.[21]

As expected in our study, we identified a significant increase in the IIEF-5 score, which assesses specific improvement in sexual function, at 4 and 8 weeks (4.10 ± 5.32 and 3.33 ± 4.77, respectively; P < .01). These findings are consistent with the aforementioned previous studies on the effects of tadalafl on ED. Although we included BIA measures in our analysis, the effects of tadalafl on body composition have not yet been well-studied and clarified. Therefore, we are not surprised by the lack of effect of tadalafl on BIA measures. However, we had not anticipated the lack of effect of tadalafl on free oxygen radicals at 8 weeks. We had postulated that as a PDE-5I, tadalafl would increase the concentration of NO and, therefore, reduce the level of free radicals. We had based our hypothesis on previous studies that had indicated and lowering of free radicals with NO release from endothelial cells, except under ischemic conditions.[22–24] Our findings may reflect the multiple health and environmental factors that influence free radical levels, including exercise, vitamins, healthy diet, smoking, obesity, and aging which modify the antioxidant capacity and, hence, levels of free radicals.[25]

Consequently, it was difficult to evaluate the direct association between the use of tadalafl and free radical test results in our study.

The mean total testosterone level among our participants was 5.92 ± 2.64 ng/mL, with normal levels ranging between 3.5 and 9 ng/mL, among study populations and countries. Only 23% of our participants were classified as having a low testosterone level (<3.5 ng/mL), with the other participants having a normal level of testosterone, despite the presence of andropause symptoms, including ED. Possible explanations for these cases, which are common in clinical practice, include changes in the sensitivity of tissues and receptors to hormones, differences in hormone concentrations in tissues, degeneration of the hormone itself, and increases in the level of sexual hormone-binding globulin (SHBG). According to previous studies, the risk of ED in andropausal men is associated with the decrease in testosterone levels. As such, traditionally, the testosterone level is used as a biochemical indicator of andropause syndrome, with the prevalence of ED being higher among those with a lower testosterone level.[26] However, a relatively recent study reported that the blood concentration of male hormones may not be representative of the amount of hormonal activity, which is influenced by the function of the hormone itself.[27] Moreover, as SHBG increases with aging, blood levels of testosterone might not accurately represent the hormone status in middle-aged individuals. Therefore, the portion of biologically active testosterone should be measured.[27] It is also important to note that there are age-related decreases in other hormones as well in men, including dehydroepiandrosterone, growth hormone, insulin-like growth factor-I, and melatonin.[28] However, according to the guidelines of the International Men’s Society and Korean Andropausal Society, testosterone replacement therapy (TRT) should be initiated when the serum level of testosterone reduces to <250 ng/dL[12] and/or in the presence of andropause symptoms, with these criteria being consistent across different countries. Therefore, the efficacy of TRT may be limited for men with andropause symptoms, including ED, who have a total testosterone level >250 ng/dL. In our study, the use of 5 mg OaD of tadalafl improved the QoL of men with andropause symptoms, including ED, regardless of whether their total testosterone level was below <250 ng/dL or not.

In terms of compliance with using tadalafl and its safety, all participants fully adhered to the study protocol over the 8 weeks of the study period, with no drop-outs and good drug tolerability. This might reflect the convenience of the OaD dose and the relative short duration of prescription (8 weeks). The recommendation provided by physicians regarding the appropriateness of tadalafl as an optimal treatment suited to each patient’s needs and the provision of a full explanation of the advantages and disadvantages of the drug might have helped to increase compliance. These results are consistent with those of a previous observational study that reported that physicians can influence patients’ decision regarding treatment for ED, with >86% of patients in that study either starting to use tadalafl, or switching to a 5 mg OaD dose, and continuing to treatment for 6 months.[29] A randomized, double-blind, placebo-controlled trial evaluating the effects of a 12-week prescription of a 5 mg OaD dose of tadalafl among 314 Korean men with BPH reported beneficial effects of the treatment, with the drug being well-tolerated.[30] With regards to safety, we identified only transient or mild adverse effects in our study group, which did not hinder participants’ daily function. Moreover, the 5 mg tadalafl dose had no significant effect on vital signs, despite the vasodilation effects of tadalafl. Our results confirm those of Kang et al who reported on the safety and efficacy of a 5 mg OaD dose of tadalafl among 162 Korean men. Improved blood pressure and heart rate were found after an 8-week treatment.[31] Adverse effects identified included facial flushing in 6% of patients at 4 weeks, and headaches in 4% of patients at 8 weeks.

The limitations of our study need to be acknowledged. First, this is a single group, open-labeled, before-and-after preliminary trial, without a control group, and included a relatively small number of participants (n = 40). However, we do acknowledge that even for a preliminary study, a randomized placebo-controlled trial would be more appropriate. Moreover, both QoL and ED were evaluated using self-reported questionnaires. Therefore, the objectivity of our findings is insufficient for the generalization of our results. Second, several variables, such as educational level, religion, quality of the partner relationship,
monthly income, exercise, hobbies, marital status, and frequency of sexual intercourse may affect QoL, and could have been included as confounding variables. Lastly, the 8-week period of observation, from the initial screening to the end point of the study, was relatively short, which may not be sufficiently long to fully evaluate QoL and safety of the drug.

Our study demonstrated that a daily 5 mg dose of tadalafil for 8 weeks was effective in improving overall QoL in Korean men with andropause symptoms, including ED, and was safe to use. We present an alternative treatment to improve ED and overall QoL in this clinical population. Future trials, with a larger sample size, longer duration of follow-up, a control group, and more objective assessments are needed to confirm our results.

Author contributions

Conceptualization: Keun-Sang Yum, Kang Kon Lee.

Formal analysis: Kang Kon Lee.

Investigation: Keun-Sang Yum.

Writing – original draft: Joong Gyo Lee, Byung Duk Kim, Chang Hee Han.

Writing – review & editing: Keun-Sang Yum, Joong Gyo Lee, Byung Duk Kim, Chang Hee Han, Kang Kon Lee.

References

[1] Lee MW, Park H. A study on late-onset of hypogonadism, erectile dysfunction, depression, and quality of life among middle-aged male worker [in Korean]. Korean J Adult Nurs 2013;25:483–93.
[2] Morales A, Lunenfeld B. Investigation, treatment and monitoring of late-onset hypogonadism in males. Official recommendations of ISSAM. International Society for the Study of the Aging Male Aging Male 2002;5:74–86.
[3] Kim KM. Latest knowledge of treatment in andropause [in Korean]. Korean J Health Promot 2012;1:117–21.
[4] Scaglione F, Donde S, Hassan TA, et al. Phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction: pharmacology and clinical impact of the sildenafile citrate orodispersible tablet formulation. Clin Ther 2017;39:370–7.
[5] Kim ED, Setel AD, Goldfischer ER, et al. A return to normal erectile function with tadalafil once daily after an incomplete response to as-needed PDE5 inhibitor therapy. J Sex Med 2014;11:820–30.
[6] Giuliano F, Peña BM, Mishra A, et al. Efficacy results and quality-of-life measures in men receiving sildenafile citrate for the treatment of erectile dysfunction. Qual Life Res 2001;10:359–69.
[7] Novik A, Brod M, Elbers J. Andropause and quality of life: findings from patient focus groups and clinical experts. Maturitas 2002;43:231–7.
[8] Attia AA, Hassan FA, Kamel ML, et al. Quality of life in erectile dysfunction patients and their partners responding to tadalafil versus sildenafile citrate. Egypt J Dermatol Venereol 2013;33:32–6.
[9] Bai WJ, Li HJ, Jin JJ, et al. A randomized clinical trial investigating treatment choice in Chinese men receiving sildenafile citrate and tadalafil for treating erectile dysfunction. Asian J Androl 2017;19:500–4.
[10] Morley JE, Charlton E, Patrick P, et al. Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism 2000;49:1239–42.
[11] Kim SW, Oh SJ, Paick JS, et al. Development of the Korean-translation of androgen deficiency in aging males (ADAM) questionnaire [in Korean]. Korean J Urol 2004;45:764–9.
[12] Moon KH, Chang JY. Guidelines of Andropause. Andropause. [in Korean] Koom Ja Publishers, Seoul, Korea:2009;343–7.
[13] Ware J Jr., Kosinski M, Keller SD. A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996;34:220–33.
[14] Lee SH, Yang SO. The effects of chronic musculoskeletal pain and depression on health-related quality of life by gender in community-dwelling older adults [in Korean]. J Korean Acad Community Health Nurs 2010;21:21–30.
[15] Ahn TY, Lee DS, Hong JH, et al. Validation of an abridged Korean version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction [in Korean]. Korean J Urol 2001;42:535–40.
[16] Bae JH, Kim YM, Kim KH, et al. Review on bioelectrical impedance analysis in traditional East Asian medicine [in Korean]. J Physiol Pathol Korean Med 2013;27:717–29.
[17] Dal Negro RW, Visconti MC, Micheleto C, et al. Normal values and reproducibility of the major oxidative stress obtained thanks to FORM system. G Ital Mal Torace 2003;57:199–209.
[18] Bagatell CJ, Bremner WJ. Androgens in men—uses and abuses. N Engl J Med 1996;334:707–15.
[19] Tong SF, Ng CJ, Lee BC, et al. Effect of long-acting testosterone undecanoate on treatment quality of life in men with testosterone deficiency syndrome: a double blind randomized controlled trial. Asian J Androl 2012;14:604–11.
[20] Oelke M, Shinghal R, Sontaq A, et al. Time to onset of clinically meaningful improvement with tadalafil 5 mg once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: analysis of data pooled from 4 pivotal, double-blind, placebo controlled studies. J Urol 2015;193:1581–9.
[21] Rubio-Auriles E, Kim ED, Rosen RC, et al. Impact on erectile function and sexual quality of life of couples: a double-blind, randomized, placebo-controlled trial of tadalafil taken once daily. J Sex Med 2009;6:1314–23.
[22] Anaya-Prado R, Toledo-Pereyra LH, Lentsch AB, et al. Ischemia/reperfusion injury. In: 2nd ed Cardiovasc Res 1996;32:743–51.
[23] Scaglione F, Dondi S, Hassan TA, et al. Phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction: pharmacology and clinical impact of the sildenafile citrate orodispersible tablet formulation. Clin Ther 2017;39:370–7.
[24] Kim ED, Setel AD, Goldfischer ER, et al. A return to normal erectile function with tadalafil once daily after an incomplete response to as-needed PDE5 inhibitor therapy. J Sex Med 2014;11:820–30.
[25] Novik A, Brod M, Elbers J. Andropause and quality of life: findings from patient focus groups and clinical experts. Maturitas 2002;43:231–7.
[26] Attia AA, Hassan FA, Kamel ML, et al. Quality of life in erectile dysfunction patients and their partners responding to tadalafil versus sildenafile citrate. Egypt J Dermatol Venereol 2013;33:32–6.
[27] Bai WJ, Li HJ, Jin JJ, et al. A randomized clinical trial investigating treatment choice in Chinese men receiving sildenafile citrate and tadalafil for treating erectile dysfunction. Asian J Androl 2017;19:500–4.
[28] Morley JE, Charlton E, Patrick P, et al. Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism 2000;49:1239–42.
[29] Kim SW, Oh SJ, Paick JS, et al. Development of the Korean-translation of androgen deficiency in aging males (ADAM) questionnaire [in Korean]. Korean J Urol 2004;45:764–9.